• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4594883)   Today's Articles (36)   Subscriber (49330)
For: Tsai HH. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Aliment Pharmacol Ther 2018;47:539-540. [PMID: 29341281 DOI: 10.1111/apt.14480] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Number Cited by Other Article(s)
1
Ribaldone DG, Pellicano R, Actis GC. Inflammation in gastrointestinal disorders: prevalent socioeconomic factors. Clin Exp Gastroenterol 2019;12:321-329. [PMID: 31410046 PMCID: PMC6650093 DOI: 10.2147/ceg.s210844] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Accepted: 06/24/2019] [Indexed: 12/22/2022]  Open
2
Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply. Aliment Pharmacol Ther 2018;47:540-541. [PMID: 29341277 DOI: 10.1111/apt.14486] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA